Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Incidence, presentation and outcome of toxoplasmosis in HIV infected in the combination antiretroviral therapy era

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The efficacy of topical agents used in wounds for managing chronic biofilm infections: A systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Management of MDR-TB in HIV co-infected patients in eastern europe: results from the TB:HIV study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Long-term mortality and causes of death associated with Staphylococcus aureus bacteremia. A matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cervical cancer risk in women living with HIV across four continents: A multicohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: HIV-associated incidence and prognosis of cerebral toxoplasmosis (CTX) is not well established during later years.

METHODS: From the Danish HIV Cohort Study, we identified 6325 HIV-infected individuals. We assessed incidence, mortality, predictive and prognostic factors of CTX during the pre-combination antiretroviral therapy (pre-cART; 1995-1996) and cART-era (1997-2014). Adjusted incidence rate ratios (aIRR), mortality rate ratios (aMRR) and 95% confidence intervals (CI) were assessed using Poisson regression analysis.

RESULTS: CTX IR was 1.17/1000 PYR (95% CI 0.93-1.47). We observed no change in CTX-risk in the first year after HIV-diagnosis, but a substantial reduction in mortality in the first 3 months after CTX diagnosis when comparing the cART-era to the pre-cART-era; {(aIRR: 0.79; 95% CI: 0.37-1.72) (aMRR: 0.15; 95% CI: 0.06-0.38)}. For individuals surviving the first year after HIV-diagnosis or the first 3 months after CTX-diagnosis, IRR and MRR had declined to minimal levels {(aIRR: 0.06; 95% CI: 0.03-0.10); (aMRR: 0.02; 95% CI: 0.01-0.05)}. Three years after CTX-diagnosis 30% of the patients still had neurological deficits.

CONCLUSION: Although, CTX remains an important cause of morbidity and mortality in the cART-era, with high prevalence of neurological sequelae, incidence and mortality has largely declined, especially among those surviving the first year after diagnosis.

Original languageEnglish
JournalJournal of Infection
Volume75
Issue number3
Pages (from-to)263-273
ISSN0163-4453
DOIs
Publication statusPublished - 1 Sep 2017

    Research areas

  • Journal Article

ID: 50596551